Human medicines European public assessment report (EPAR): Tarceva, erlotinib, Date of authorisation: 19/09/2005, Revision: 34, Status: Authorised

Human medicines European public assessment report (EPAR): ReFacto AF, moroctocog alfa, Date of authorisation: 13/04/1999, Revision: 41, Status: Authorised

Human medicines European public assessment report (EPAR): Toviaz, fesoterodine, Date of authorisation: 20/04/2007, Revision: 30, Status: Authorised

Human medicines European public assessment report (EPAR): Ryzodeg, insulin degludec,insulin aspart, Date of authorisation: 21/01/2013, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Viramune, nevirapine, Date of authorisation: 04/02/1998, Revision: 45, Status: Authorised

Opinion/decision on a Paediatric investigation plan (PIP): Opdualag, Nivolumab,Relatlimab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Neoplasms benign, malignant and unspecified (incl cysts and polyps), PIP number: P/0458/2023

EMEA-003484-PIP01-23

Human medicines European public assessment report (EPAR): Mirvaso, brimonidine, Date of authorisation: 20/02/2014, Revision: 14, Status: Authorised

PSUSA/00002943/202406

Human medicines European public assessment report (EPAR): Nepexto, etanercept, Date of authorisation: 20/05/2020, Revision: 15, Status: Authorised